Hangzhou Heda Industry Fund
VC Fund
Hangzhou Heda Industry Fund is an investment firm.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 13%
Last updated:
For AI agents: llms.txt
Industries Hangzhou Heda Industry Fund invests in
Stages Hangzhou Heda Industry Fund invests in
Countries Hangzhou Heda Industry Fund invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Mr. Jin Yufeng
|
|||
4 more contacts available
Investment Focus
Industry
- Biotechnology 5 (63%)
- Medical 3 (38%)
- Health Care 3 (38%)
- Pharmaceutical 3 (38%)
- Manufacturing 2 (25%)
Stage
- Series A 3 (38%)
- Series B 3 (38%)
- Seed 1 (13%)
- Venture - Series Unknown 1 (13%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Mr. Jin Yufeng
President
|
President | Total investments: 6 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
SEED is a company engaged in the research and development and production of foldable ultra-thin flexible glass (UTG). | Series B / Sep 12, 2025 | |
|
|
Chance Pharmaceuticals provides, discovers, develops, and commercializes inhalation therapies for the world’s debilitating diseases such as chronic obstructive pulmonary disease, asthma, pulmonary arterial hypertension, and central nervous system disorders. | Venture - Series Unknown / Mar 04, 2025 | |
|
|
Medtech Technology is a firm that develops innovative ophthalmic medical devices.It has developed its own artificial lens production and research technology platform, as well as a technological barrier to high-end artificial lens manufacture. | $28.2M / Series B / Sep 14, 2024 | |
|
|
Hegeia Biotechnology is a company that focused on the research and development of siRNA, tiny nucleic acid attached delivery medicines. | $13.8M / Series A / Mar 28, 2024 | |
|
|
Hengyu Biotechnology is a CXO platform founded by a scientific research team that provides biosafety testing and related process validation. | $27.8M / Series B / Mar 11, 2024 | |
|
|
Ceram Pharmaceuticals is a biotech firm that uses epigenetics to carry out R&D of drugs and diagnostic treatments for cancer and diseases. | $14M / Series A / Dec 25, 2023 | |
|
|
Innolake Biopharm clinical-stage biotech company with a focus on oncology and autoimmune disease areas. | $14.1M / Series A / Jun 05, 2023 | |
|
|
Blue Wave is a producer of Industrial IoT and Internet of Vehicles chips. | $14.5M / Seed / May 04, 2023 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Hangzhou Heda Industry Fund invest in?
Hangzhou Heda Industry Fund invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Hangzhou Heda Industry Fund?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Hangzhou Heda Industry Fund?
The team at Hangzhou Heda Industry Fund includes Mr. Jin Yufeng (President). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!